Clearstone Central Laboratories announced that business analytics software giant SAS has recently published a customer success story that features the extensive history between the two companies working alongside to accelerate clinical trails with clean, on-time data.
Every year, pharmaceutical companies deliver an ever-broadening range of medications that improve patient health and save countless lives. But the clinical trial phase of drug development is a risky proposition—expensive, highly regulated, and critical to the market approval of a drug. Increasingly, pharmaceutical executives are turning to Clearstone to manage this complex process of creating, aggregating, and delivering highly structured, reliable, and timely data.
SAS has allowed Clearstone to effectively work with large volumes of data that previously would require substantially more time and resources. Multiple tasks can be run simultaneously, allowing for time efficiencies. This additional flexibility has enabled Clearstone to rapidly scale its business around the world and expand its service offering to include data mining and analytical services that allow Clearstone to predict aspects of a trial using historical data.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.